USANA Health Sciences, Inc. (NYSE:USNA) Director Sells $14,830.00 in Stock

USANA Health Sciences, Inc. (NYSE:USNA - Get Free Report) Director John Turman Fleming sold 500 shares of the firm's stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $29.66, for a total value of $14,830.00. Following the completion of the sale, the director now directly owns 4,200 shares in the company, valued at approximately $124,572. The trade was a 10.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

USANA Health Sciences Price Performance

USNA traded down $0.18 on Friday, reaching $29.60. 171,587 shares of the company's stock were exchanged, compared to its average volume of 135,645. The stock's fifty day moving average price is $27.93 and its 200-day moving average price is $31.20. USANA Health Sciences, Inc. has a twelve month low of $23.10 and a twelve month high of $48.85. The stock has a market cap of $551.24 million, a PE ratio of 10.46, a P/E/G ratio of 0.93 and a beta of 0.63.

USANA Health Sciences (NYSE:USNA - Get Free Report) last posted its quarterly earnings results on Tuesday, April 22nd. The company reported $0.73 EPS for the quarter, topping the consensus estimate of $0.70 by $0.03. The business had revenue of $249.54 million for the quarter, compared to analyst estimates of $243.08 million. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. During the same quarter in the previous year, the firm earned $0.86 EPS. As a group, research analysts predict that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current fiscal year.

Institutional Trading of USANA Health Sciences

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Empowered Funds LLC purchased a new position in USANA Health Sciences during the first quarter worth about $687,000. Petrus Trust Company LTA acquired a new stake in USANA Health Sciences in the 1st quarter valued at approximately $362,000. Jacobs Levy Equity Management Inc. raised its position in USANA Health Sciences by 46.2% in the first quarter. Jacobs Levy Equity Management Inc. now owns 188,511 shares of the company's stock valued at $5,084,000 after purchasing an additional 59,535 shares during the period. AQR Capital Management LLC boosted its position in shares of USANA Health Sciences by 82.8% during the first quarter. AQR Capital Management LLC now owns 21,845 shares of the company's stock worth $589,000 after buying an additional 9,894 shares during the period. Finally, Magnetar Financial LLC acquired a new stake in shares of USANA Health Sciences in the first quarter valued at $324,000. 54.25% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on USNA. Sidoti lowered shares of USANA Health Sciences from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, February 18th. DA Davidson lowered their price objective on USANA Health Sciences from $38.00 to $36.00 and set a "neutral" rating on the stock in a report on Thursday, February 27th. Finally, Wall Street Zen raised USANA Health Sciences from a "hold" rating to a "buy" rating in a report on Thursday, May 22nd.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.